Company intelligence / Profile preview
Genflow Biosciences
London, England, United Kingdomgenflowbio.com ↗
- Ownership
- Public · GENF
- Development stage
- Preclinical
01
Overview
Received positive feedback from FDA to proceed with identifying appropriate animal models through pilot, proof-of-concept studies. Scheduled to begin clinical trials for GF-1002 in 2025 to explore benefits in treating MASH.
- Therapeutic areas
- Metabolic DisordersOther
- Modalities
- Gene therapy
- Industry
- Biotech
02
Drug pipeline
8 assets7 more assets in the full pipeline.
03
Partnerships
Magnitude Biosciences Ltd
04
Financials
- Market cap
- $13.9M
- Total revenue
- $0
- Enterprise value
- $13.1M
Beyond the preview
Go deeper on Genflow Biosciences.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Genflow Biosciences.